Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Life sciences tech firm Waters' Q3 revenue, adjusted EPS beat estimates

By Reuters News


Overview

  • US life sciences technology firm's Q3 revenue rose, beating analyst expectations

  • Adjusted EPS for Q3 grew 21% and beat analyst expectations

  • Company acquired MOBILion Systems to expand mass spectrometry capabilities


Outlook

  • Waters raises full-year 2026 total revenue guidance to $6.479 bln-$6.497 bln

  • Company lifts full-year 2026 adjusted EPS outlook to $14.60-$14.70

  • Waters expects Q4 2026 revenue of $1.801 bln-$1.819 bln and adjusted EPS of $4.58-$4.68


Result Drivers

  • CONSUMABLES AND INSTRUMENTS - Co said double-digit growth in instrument and chemistry consumables sales in Analytical Sciences Division was driven by new product innovation, strong execution, and higher customer testing volume

  • REAGENT SALES - Biosciences Division saw high single-digit growth in reagents, with both research and clinical reagents contributing, reflecting a 400bps acceleration in year-over-year growth

  • INSTRUMENT REPLACEMENT AND SPECIALTY DEMAND - LC-MS instrument growth was driven by robust replacement trends and demand related to GLP-1s, PFAS, and India generics, per CEO


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$1.77 bln

$1.75 bln (20 Analysts)

Q3 Adjusted EPS

Beat

$4.10

$4 (20 Analysts)

Q3 EPS

$0.82


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Waters Corp is $470.00, about 4.6% above its November 2 closing price of $449.53

  • The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 24 three months ago


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

  • Nov 2 - IDEXX raises forecast, betting diagnostics can offset weak vet visits


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.